Enhanced pH-responsiveness, cellular trafficking, cytotoxicity and long-circulation of PE gylated liposomes with post-insertion technique using gemcitabine as a model drug

Pharmaceutical Research

Volumn 32, Issue 7, 2015, Pages 2428-2438

  Xu, Hongtao ^a   Paxton, James W ^a   Wu, Zimei ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Endosome escape; Gemcitabine; Long circulation; PEGylation; pH sensitive liposomes (PSL); post insertion

Indexed keywords

GEMCITABINE; LIPOSOME; MACROGOL 2000; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG CARRIER; MACROGOL DERIVATIVE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CELL MIGRATION; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; CYTOTOXICITY; DRUG HALF LIFE; DRUG RELEASE; ENDOSOME; MACROPHAGE; NONHUMAN; PANCREATIC CANCER CELL LINE; PH; PLASMA CLEARANCE; PRIORITY JOURNAL; RAT; ANALOGS AND DERIVATIVES; ANIMAL; BLOOD; CELL SURVIVAL; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; DRUG FORMULATION; DRUG RESISTANCE; ENDOCYTOSIS; HUMAN; METABOLISM; PARTICLE SIZE; SPRAGUE DAWLEY RAT; SURFACE PROPERTY; TUMOR CELL LINE;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CELL LINE, TUMOR; CELL SURVIVAL; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG CARRIERS; DRUG COMPOUNDING; DRUG LIBERATION; DRUG RESISTANCE, NEOPLASM; ENDOCYTOSIS; ENDOSOMES; HUMANS; HYDROGEN-ION CONCENTRATION; LIPOSOMES; MACROPHAGES; PARTICLE SIZE; POLYETHYLENE GLYCOLS; RATS, SPRAGUE-DAWLEY; SURFACE PROPERTIES;

EID: 84930179484     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-015-1635-0     Document Type: Article

References (40)

1. Laouini A, Jaafar-Maalej C, Limayem-Blouza I, Sfar S, Charcosset C, Fessi H. Preparation, characterization and applications of liposomes: state of the Art. J Colloid Sci Biotechnol. 2012;1:147-68.
2. Hilbig A, Oettle H. Gemcitabine in the treatment of metastatic pancreatic cancer. Expert Rev Anticancer Ther. 2008;8:511-23.
3. Xu H, Paxton J, Lim J, Li Y, Zhang W, Duxfield L, et al. Development of high-content gemcitabine PEGylated liposomes and their cytotoxicity on drug-resistant pancreatic tumour cells. Pharm Res. 2014;31:2583-92.
4. Karanth H, Murthy RSR. pH-Sensitive liposomes - principle and application in cancer therapy. J Pharm Pharmacol. 2007;59:469-83.
5. Fattal E, Couvreur P, Dubernet C. "Smart" delivery of antisense oligonucleotides by anionic pH-sensitive liposomes. Adv Drug Deliv Rev. 2004;56:931-46.
6. Slepushkin VA, Simões S, Dazini P, Newman MS, Guo LS, Lima MCP, et al. Sterically stabilized pH-sensitive liposomes. J Biol Chem. 1997;272(4):2382-8.
7. Geisow MJ, Evans WH. pH in the endosome measurements during pinocytosis and receptor-mediated endocytosis. Exp Cell Res. 1984;150:36-46.
8. Murphy RF, Powers S, Cantor CR. Endosome pH measured in single cells by dual fluorescence flow cytometry: rapid acidification of insulin to pH 6. J Cell Biol. 1984;98:1757-62.
9. Sr S, Moreira JN, Fonsecab C, Düzgünes N, Lima MCP. On the formulation of pH-sensitive liposomes with long circulation times. Adv Drug Deliv Rev. 2004;56:947-65.
10. Lee ES, Na K, Bae YH. Doxorubicin loaded pH-sensitive polymeric micelles for reversal of resistant MCF-7 tumor. J Control Release. 2005;103:405-18.
11. Leite EA, Souza CM, Carvalho-Júnior ÁD, Coelho LG, Lana ÂM, Cassali GD, et al. Encapsulation of cisplatin in long-circulating and pH-sensitive liposomes improves its antitumor effect and reduces acute toxicity. Int J Nanomedicine. 2012;7:5259-69.
12. Torchilin VP, Zhou F, Huang L. pH-sensitive liposomes. J Liposome Res. 1993;3:201-5.
13. III DEO, Peppas NA. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm. 2006;307:93-102.
14. Gabizon A, Shmeeda H, Barenholz Y. Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies. Clin Pharmacokinet. 2003;42(5):419-36.
15. Hong M-S, Lim S-J, Oh Y-K, Kim C-K. pH-sensitive, serum-stable and long-circulating liposomes as a new drug delivery system. J Pharm Pharmacol. 2002;54:51-8.
16. Remaut K, Lucas B, Braeckmans K, Demeester J, Smedt SCD. Pegylation of liposomes favours the endosomal degradation of the delivered phosphodiester oligonucleotides. J Control Release. 2007;117:256-66.
17. Iden DL, Allen TM. In vitro and in vivo comparison of immunoliposomes made by conventional coupling techniques with those made by a new post-insertion approach. Biochim Biophys Acta. 2001;1513:207-16.
18. Li CL, Cui JX, Wang CX, Zhang L, Li YH, Zhang L, et al. Development of pegylated liposomal vinorelbine formulation using"post-insertion" technology. Int J Pharm. 2010;391:230-6.
19. Kanai M, Yoshimura K, Asada M, Imaizumi A, Suzuki C, Matsumoto S, et al. A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer. Cancer Chemother Pharmacol. 2011;68:157-64.
20. Ali S, Ahmad A, Banerjee S, Padhye S, Dominiak K, Schaffert JM, et al. Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF. Cancer Res. 2010;70(9):3606-17.
21. Abbruzzese JL, Grunewald R, Weeks EA, Gravel D, Adams T, Nowak B, et al. A Phase I Clinical, Plasma, and Cellular Pharmacology Study of Gemcitabine. J ClinOncol. 1991;9:491-8.
22. Storniolo AM, Allerheiligen SR, Pearce HL. Preclinical, pharmacologic, and phase I studies of gemcitabine. Semin Oncol. 1997;24:S7-2-S7.
23. Lee RJ, Low PS. Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro. Biochim Biophys Acta. 1995;1233:134-44.
24. K-i O, Una K, Minatoa K, Tanakab K-I, Higakia K, Kimura T. Determinants for in vivo anti-tumor effects of PEG liposomal doxorubicin: importance of vascular permeability within tumors. Int J Pharm. 2008;359:234-40.
25. Sudimack JJ, Guo W, Tjarks W, Lee RJ. A novel pH-sensitive liposome formulation containing oleyl alcohol. Biochim Biophys Acta. 2002;1564:31-7.
26. El-Sayed A, Futaki S, Harashima H. Delivery of macromolecules using arginine-rich cell-penetrating peptides: ways to overcome endosomal entrapment. AAPS J. 2009;11:13-22.
27. Costa P. An alternative method to the evaluation of similarity factor in dissolution testing. Int J Pharm. 2001;220:77-83.
28. Working PK, Newmanl MS, Huang SK, Mayhew E, Vaage J, Lasicl DD. Pharmacokiketics, biodistribution and therapeutic efficacy of doxorubicin encapsulated in stealth liposomes (doxil). J Liposome Res. 1994;4(1):667-87.
29. Simoes S, Slepushkin V, Duzgunes N, Lima MCP. On the mechanisms of internalization and intracellular delivery mediated by pH-sensitive liposomes. Biochim Biophys Acta. 2001;1515:23-37.
30. Paliwal SR, Paliwal R, Vyas SP. A review of mechanistic insight and application of pH-sensitive liposomes in drug delivery. Drug Deliv. 2014. In press.
31. Kim I-Y, Kang Y-S, Lee DS, Park H-J, Choi E-K, Oh Y-K, et al. Antitumor activity of EGFR targeted pH-sensitive immunoliposomes encapsulating gemcitabine in A549 xenograft nude mice. J Control Release. 2009;140:55-60.
32. Graeser R, Bornmann C, Esser N, Ziroli V, Jantscheff P, Unger C, et al. Antimetastatic effects of liposomal gemcitabine and empty liposomes in an orthotopic mouse model of pancreatic cancer. Pancreas. 2009;38:330-7.
33. Cosco D, Bulotta A, Ventura M, Celia C, Calimeri T, Perri G, et al. In vivo activity of gemcitabine-loaded PEGylated small unilamellar liposomes against pancreatic cancer. Cancer Chemother Pharmacol. 2009;64:1009-20.
34. Bersani S, Vila-Caballer M, Brazzale C, Barattin M, Salmaso S. pH-sensitive stearoyl-PEG-poly(methacryloyl sulfadimethoxine) decorated liposomes for the delivery of gemcitabine to cancer cells. Eur J Pharm Biopharm. 2014.
35. Chu C, Dijkstra J, Lai M, Hong K, Szoka FC. Efficiency of cytoplasmic delivery by pH-sensitive liposomes to cells in culture. Pharm Res. 1990;7(8):824-34.
36. Li C, Cui J, Li Y, Wang C, Li Y, Zhang L, et al. Copper ion-mediated liposomal encapsulation of mitoxantrone: The role of anions in drug loading, retention and release. Eur J Pharm Sci. 2008;34:333-44.
37. Cui J, Li C, Guo W, Li Y, Wang C, Zhang L, et al. Direct comparison of two pegylated liposomal doxorubicin formulations: is AUC predictive for toxicity and efficacy? J Control Release. 2007;118:204-15.
38. Maruyama K. Intracellular targeting delivery of liposomal drugs to solid tumors based on EPR effects. Adv Drug Deliv Rev. 2011;63:161-9.
39. Yin H, Liao L, Fang J. Enhanced Permeability and Retention (EPR) effect based tumor targeting: the concept, application and prospect. JSM Clin Oncol Res. 2014;2(1):1010.
40. Fenske DB, Cullis PR. Liposomal nanomedicines. Expert Opin Drug Deliv. 2008;5(1):25-44.